G-Magsulph2.5 gm/5 ml

G-Magsulph has several distinct clinical uses depending on the route of administration and formulation:

Established / FDA-approved uses (parenteral)

• Prevention and control of seizures in pre-eclampsia and eclampsia (obstetric emergency use, IV/IM).
• Correction and prevention of hypomagnesemia in patients unable to maintain adequate levels through diet.
• Treatment of acute severe hypomagnesemia accompanied by symptoms (e.g., seizures, arrhythmias).

Guideline-supported / adjunctive uses

• Adjunct treatment for severe acute asthma exacerbations unresponsive to first-line bronchodilators (IV infusion), as supported by emergency medicine guidelines.
• Treatment of torsades de pointes and certain other ventricular arrhythmias, particularly when associated with hypomagnesemia (IV use), per cardiac life-support guidelines.
• Component of tocolysis regimens in selected obstetric settings (use varies by institutional protocol).

Oral / rectal use

• Short-term relief of occasional constipation (oral saline laxative).
• Bowel evacuation before certain procedures (as directed by a physician).

Topical use

• Soaking solution (Epsom salt) for minor muscle aches and soreness — a traditional, non-prescription use with limited high-quality clinical evidence.

The intended use and route must be confirmed with a physician, as dosing and risk profiles differ substantially between obstetric/IV emergency use and oral laxative use.

Each formulation contains Magnesium Sulfate as the active ingredient. Available forms include:

• Injectable solution for IV/IM use (commonly 10%, 20%, or 50% concentrations, e.g., 500 mg/mL in the 50% formulation).
• Oral powder/granules (e.g., Epsom salt, USP) for use as a laxative when dissolved in water.
• Topical/bath-soak preparations.

Strength and formulation available in Bangladesh should be confirmed on the product label, as Magnesium Sulfate injection is typically a hospital/institutional product.

G-Magsulph is an inorganic salt providing magnesium and sulfate ions. Magnesium is an essential cation involved in numerous enzymatic reactions, neuromuscular transmission, cardiac excitability, and vascular tone. Administered parenterally, G-Magsulph acts as a central nervous system depressant and anticonvulsant, and as a smooth-muscle relaxant contributing to vasodilation and tocolysis. Administered orally, unabsorbed G-Magsulph draws water into the bowel lumen osmotically, producing a laxative effect. G-Magsulph is used across obstetric, emergency, and general medical settings, with dosing and monitoring requirements that differ markedly by indication and route.

G-Magsulph belongs to the following therapeutic/pharmacologic classes depending on use:

• Anticonvulsant / antiepileptic agent (obstetric use for pre-eclampsia/eclampsia).
• Electrolyte replenisher (magnesium supplement, for hypomagnesemia).
• Antiarrhythmic agent (adjunct, for torsades de pointes).
• Saline/osmotic laxative (oral use).
• Tocolytic agent (adjunct, selected obstetric protocols).

Mechanism of action

Magnesium Sulfate provides magnesium ions, which act as a physiological calcium antagonist. Key pharmacological effects include:

• Neuromuscular/CNS effects: Reduces acetylcholine release at the neuromuscular junction and depresses the central nervous system, reducing seizure threshold excitability — the basis for its anticonvulsant effect in eclampsia.
• Vascular smooth muscle: Magnesium acts as a calcium channel blocker at smooth muscle, producing vasodilation and reducing uterine contractility (tocolysis), and contributing to bronchodilation in severe asthma.
• Cardiac effects: Stabilizes cardiac membranes and prolongs the effective refractory period, useful in suppressing torsades de pointes.
• Laxative effect (oral route): Poorly absorbed magnesium and sulfate ions remain in the intestinal lumen, exerting an osmotic effect that draws water into the bowel, increasing stool bulk and stimulating peristalsis.

Pharmacokinetics

Following IV administration, onset of anticonvulsant action is immediate; after IM administration, onset occurs within about 1 hour. Magnesium is not metabolized and is excreted almost entirely by the kidneys; excretion is proportional to the glomerular filtration rate, so renal impairment substantially increases the risk of accumulation and toxicity. Oral Magnesium Sulfate is poorly absorbed systemically (a small fraction may be absorbed), acting mainly locally within the gut.

For IV/IM use, G-Magsulph is administered by trained healthcare personnel with continuous monitoring of vital signs, reflexes, and magnesium levels; infusion pumps should be used for accuracy. For oral use, dissolve the prescribed dose completely in water and drink promptly; adequate fluid intake should be maintained. For topical soaks, dissolve in warm water as directed. Do not self-administer the injectable form.

Clinically significant interactions

• CNS depressants / neuromuscular blocking agents: Concurrent use with these agents may potentiate CNS and neuromuscular depression, increasing the risk of respiratory depression when G-Magsulph is given parenterally.
• Calcium channel blockers (e.g., nifedipine): Concomitant use with IV G-Magsulph may cause additive hypotension and neuromuscular blockade.
• Digoxin: IV G-Magsulph should be used cautiously in digitalized patients, as changes in magnesium and calcium balance can affect cardiac conduction; concurrent calcium administration in this setting requires caution.
• Oral tetracyclines, fluoroquinolones, and bisphosphonates: Oral G-Magsulph can form non-absorbable complexes with these drugs, reducing their absorption; separate dosing by at least 2–3 hours.
• Other magnesium-containing products or potassium-sparing agents affecting renal excretion: May increase risk of hypermagnesemia; use with caution, especially in renal impairment.

Common (parenteral use)

• Flushing, feeling of warmth
• Sweating
• Hypotension
• Injection site irritation

Serious (dose-related, parenteral use — signs of magnesium toxicity)

• Loss of deep tendon reflexes (hyporeflexia)
• Muscle weakness, flaccid paralysis
• Respiratory depression or arrest
• Cardiac arrhythmias, heart block, cardiac arrest (at very high levels)

See Precautions and Warnings and Overdose Effects for monitoring and management of magnesium toxicity.

Oral/laxative use

• Abdominal cramping, bloating
• Diarrhea, loose stools
• Nausea
• Electrolyte disturbances with excessive or prolonged use

G-Magsulph is widely used in pregnancy specifically for the treatment and prevention of eclamptic seizures and as a component of tocolytic/neuroprotective regimens, where its benefit in this setting is well established under close medical supervision. However, use for other indications during pregnancy, and prolonged use (generally beyond 5–7 days) for tocolysis, should be limited, as prolonged fetal exposure has been associated with fetal/neonatal bone abnormalities. G-Magsulph should be used only if clearly needed and under direct physician supervision, with the potential benefit weighed against potential risk in each situation. G-Magsulph is excreted in breast milk in small amounts; it is generally considered compatible with breastfeeding at usual doses, but a physician should be consulted, particularly with prolonged or high-dose parenteral use.

Magnesium toxicity monitoring (IV/IM use)

G-Magsulph has a narrow margin between therapeutic and toxic serum levels when given parenterally. Close monitoring of deep tendon reflexes, respiratory rate, urine output, and serum magnesium concentration is required throughout treatment. Early signs of toxicity include loss of patellar reflexes and flushing; progression can lead to respiratory depression and cardiac arrest. Calcium gluconate should be readily available as the antidote for severe magnesium toxicity.

Renal impairment

Because magnesium is excreted almost entirely by the kidneys, patients with renal impairment (including those receiving oral or rectal G-Magsulph) are at significantly increased risk of magnesium accumulation and toxicity. Dose reduction and more intensive monitoring of serum magnesium levels are required in this population.

Oral/laxative use

G-Magsulph used as a laxative should not be used regularly or for a prolonged period without medical advice, as this may cause fluid/electrolyte imbalance or mask underlying bowel disease. Discontinue and consult a physician if constipation persists beyond a few days or is accompanied by abdominal pain, nausea, or vomiting.

Other precautions

Use with caution in myasthenia gravis (may worsen neuromuscular weakness) and in patients receiving concurrent CNS depressants or neuromuscular blocking agents (see Interactions).

Overdose or excessive accumulation of G-Magsulph (hypermagnesemia), particularly with parenteral use, can cause loss of deep tendon reflexes, muscle weakness, hypotension, respiratory depression, heart block, and cardiac arrest. In cases of suspected overdose or symptoms of magnesium toxicity, seek immediate medical attention or contact emergency services / a poison control center. Management in a medical facility may include stopping the infusion, supportive respiratory and cardiac care, and administration of IV calcium gluconate as an antidote, along with measures to enhance magnesium elimination in severe cases. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Injectable solutions should not be used if the container shows particulate matter or discoloration; discard unused portions of opened multi-dose vials as directed by institutional protocol.

Pregnancy

See Pregnancy and Lactation section — G-Magsulph is established therapy for eclampsia/pre-eclampsia seizure prevention but requires caution with prolonged use.

Pediatric use

Safety and efficacy of G-Magsulph for indications such as severe asthma exacerbation are supported by pediatric emergency medicine literature and used off-label with weight-based dosing under specialist supervision; for other parenteral indications, use in children should be directed by a pediatric specialist. Oral use as a laxative in young children should only be under medical guidance.

Elderly

Elderly patients, particularly those with reduced renal function, are at higher risk of magnesium accumulation and toxicity; dose adjustment and closer monitoring are recommended.

Renal impairment

Use with caution and reduced dosing; see Precautions and Warnings.

Hepatic impairment

No specific dose adjustment is well established; magnesium is renally rather than hepatically eliminated.

Duration of parenteral G-Magsulph therapy depends on indication: in eclampsia/pre-eclampsia, treatment is typically continued for 24 hours after delivery or after the last seizure, per institutional protocol; for tocolysis, prolonged use beyond 5–7 days is generally avoided due to fetal risk (see Pregnancy and Lactation). For asthma or arrhythmia, it is typically given as a single adjunct dose or short infusion. Oral use as a laxative is intended for short-term, occasional use only and should not be continued for more than a few days without consulting a physician.

Anticonvulsant (obstetric use); electrolyte replenisher; antiarrhythmic adjunct; saline/osmotic laxative; tocolytic adjunct.

Magnesium ions from Magnesium Sulfate act as a physiological calcium antagonist, reducing acetylcholine release at the neuromuscular junction, depressing CNS excitability, relaxing vascular and uterine smooth muscle, and stabilizing cardiac membrane conduction. Orally, unabsorbed magnesium and sulfate ions exert an osmotic laxative effect within the intestinal lumen.

Parenteral G-Magsulph is used in pediatric emergency care, notably as an adjunct for severe acute asthma exacerbations refractory to standard bronchodilator therapy, with dosing weight-based and administration supervised by a specialist; safety and efficacy for other parenteral pediatric indications should be individually assessed by a pediatric specialist, as formal labeling for some uses is limited in children. Oral G-Magsulph for constipation in children should only be used under a physician's direction, with dosing adjusted for age and weight.